Relief of
chronic arterial obstruction using intravenous
brinase. A control study.
FitzGerald DE, Frisch EP, Milliken JC
Scand J Thorac Cardiovasc Surg
1979;13(3):327-32
A therapeutic trial using placebo or the
thrombolytic enzyme brinase was carried out in a
group of patients with chronic arterial
obstruction. The patients were observed for 3
months before receiving six intravenous infusions
of either saline or brinase over a period of 2
weeks. Ankle blood pressure, Doppler ultrasound
scanning, and arteriography were used to establish
diagnosis in the patients. No changes were
observed during the 3-month pre-observation
period. After six brinase infusions,
recanalization of 17 out of 27 obstructed arterial
segments was recorded and the number of patent
segments increased from 11 to 27. No improvement
was observed in the placebo-treated patients. The
differences between brinase and placebo treatment
was statistically significant.
Pancreatic enzyme replacement
therapy: comparative effects of conventional and
enteric-coated microspheric pancreatin and
acid-stable fungal enzyme preparations on
steatorrhoea in chronic pancreatitis.
Schneider MU, Knoll-Ruzicka ML, Domschke S,
Heptner G, Domschke W
Hepatogastroenterology 1985 Apr;32(2):97-102
The therapeutic effectiveness of a conventional
(Pankreon-Granulat) and an acid-protected (Kreon)
porcine pancreatic enzyme preparation, and an
acid-stable fungal enzyme preparation (Nortase) in
the treatment of severe pancreatogenic
steatorrhoea was investigated. The study comprised
17 patients with chronic pancreatitis and exocrine
pancreatic insufficiency with (A) or without (B) a
previous Whipple's procedure (B II resection +
partial duodenopancreatectomy). With all three
enzyme preparations, a significant (p less than
0.05) reduction in the total faecal fat
excretion/day was achieved. In therapy group A,
this reduction was, on average, 58% for Kreon
(100,000 U lipase/day), 67% for Pankreon-Granulat
(360,000 U lipase/day) and 54% for Nortase (75,000
U lipase/day), the respective figures for therapy
group B being 58%, 52% and 46% at identical
dosages. Thus, in both groups, the effect produced
by the conventional porcine pancreatic enzyme
preparation and the acid-protected porcine or the
acid-stable fungal enzyme preparation was largely
equivalent, although the latter two preparations
were administered at only 1/4 of the dosages of
the former preparation. On the basis of the
respective average reduction in total faecal fat
excretion and average number of stools/day, it
would appear that in patients with chronic
pancreatitis and prior Whipple's procedure,
Pankreon-Granulat should be administered for
enzyme replacement while in patients with an
intact upper gastrointestinal tract, Kreon should
be administered, in the treatment of steatorrhoea
in chronic pancreatitis.
Unique
features and application of non-animal derived
enzymes.
Rachman B.
Clinical Nutrition Insights 1997; 5(10)
No abstract.
Enzyme
Nutrition: The Food Enzyme Concept.
Howell E.
Wayne, NJ; Aver' Publishing Group,
1985 Percival M. Nutritional Pearls (vol 35)
No abstracts found -- book review
Hepatoprotective activity of
polyphenolic compounds from Cynara scolymnus
against CCl4 toxicity in isolated rat
hepatocytes.
Adzet T, Camarasa J, Laguna JC
J Nat Prod. 50: 612, 1987.
No abstract.
Die
Artischocke - eine Heilpflanze mit Geschichte und
zukunftperspektive.
Ernst E
Naturamed 10: 7, 1995.
No abstract.
Antidyspeptische und lipidsenkende
Wirkungen von Artischockenextrakt. Ergebnisse
klinischer Untersuchungen zur Wirksamkeit und
Vertraglichkeit von Hepar SL Forte an 553
Patienten.
Fintelmann V
Z. Allg. Med. 72:48, 1996.
No abstract.
Therapeutic profile and mechanism of
action of artichoke leaf extract: hypolipemic,
antioxidant, hepatoprotective and choleretic
properties.
Fintelmann V
Phytomed. 1996. Suppl 1: 50.
No abstract.
Uber die
lipidsenkende Wirkung von Cynarin.
Frohlich E, Zigler W
Subsidia Medica 25 (3): 5, 1973.
No abstract.
Artischockenblatterextrakt: In vitro
Nachweis einer Hemmwirkung auf die
cholesterin-Biosynthese.
Gebhardt R
Med. Welt 46: 348-35-, 1995.
No abstract.
Neue
experimentelle Erkenntnisse zur Wirkung von
Artischockenblatterextrakt.
Gebhardt R
Z Allg. Med. 72: 20-23, 1996
No abstract.
Antioxidative and protective
properties of extract from leaves of the artichoke
(Cynara scolymnus L,) against
hydro-peroxide-induced oxidative stress incultured
rat hepatocytes.
Gebhardt R
Toxicol Appl Pharmacol 144: 279-286, 1997
No abstract.
Inhibition of Cholesterol
Biosynthesis in Primary Cultured Rat Hepatocytes
by Artichoke (Cynara scolymnus L.)
Extracts.
Gebhart R
J Pharmacol Exp Ther 286: 3, 1998.
No abstract.
Polyphenols and flavonoids as
antioxidant and hepatoprotective principles of
artichoke extracts.
Gebhardt R, Fausel M, Henke B
Cell Biology and Toxicology, 1996.
No abstract.
Scavenging of peroxinitrite by a
phenolic/peroxidase system prevents oxidative
damage to DNA.
Grace SC, Salgo MG, Pryor WA
FEBS Letters 426(1): 24-8, 1998.
No abstract.
Uber
den Einfluss von cynarin auf hyperlipidamien unter
besonderer Berucksichtigung des types II
(hypercholesterinamie).
Hammerl H, Kindler K, Kranzl C, Nebosis G,
Pichler O, Studlar M
Wiener Med. Wschr. 41: 601-605, 1973.
No abstract.
Uber
eine moglichkeit der kausalen Behandlung von
Erkrankungen der Gallenwege mit einem
Artischockenpreparat.
Hammerl H, Pichler O
Wiener Med. Wschr. 107 (25/26): 545, 1957.
No abstract.
Untersuchungen uber den Einfluss
eines Artischockenextraktes auf die Serumlipide in
Hinblick auf die
Arterioskleroseprophylaxe.
Hammerl H, Pichler O
Wiener Med. Wschr. 109 (44): 853, 1959.
No abstract.
Artischocke bei
Gallenwegsdyskinesien. Neue Aspekte zur Therapie
mit Choleretika.
Held C
Z. Klin. Med. 47:92, 1992.
No abstract.
Chlorogenic acid and synthetic
chlorogenic acid derivatives: novel inhibitors of
hepatic glucose-6-phosphate
translocase.
Hemmerle H et al
J Medicinal Chemistry 40(2): 137-45, 1997.
No abstract.
Increase in choleresis by means of
artichoke extract. Results of a randomized
placebo-controlled double-blind
study.
Kirchhoff R, Beckers C, Kirchhoff GM,
Trinczek-Gartner H, Petrowicz O, Reimann HJ
Phytomedicine 1: 107, 1994.
No abstract.
Effect
of dietary caffeic and chlorogenic acids on in
vivo xenobiotic enzyme systems.
Kitts DD, Wijewickreme AN
Plant Foods for Human Nutrition 45(3):287-98,
1994.
No abstract.
The
supression of the N-nitrosating reaction by
chlorogenic acid.
Kono et al.
Biochemical Journal 312(Pt3): 947-53, 1995.
No abstract.
Antioxidant activity of polyphenolics
in diets.
Kono Y et al
Biochimica et Biophysica Acta 1335(3): 335-42,
1997.
No abstract.
Prufung
der choleretischen Aktivitat eines pflanzlichen
Cholagogums.
Kupke D, von Sanden H, Trinczek-Gartner H,
Lewin J, Blumel G, Reimann HJ:
Z. Allg. Med. (67): 1046, 1991
No abstract.
Choleretic and cholesterol lowering
properties of two artichoke extracts.
Lietti A
Filoterapia 48: 153,1977.
No abstract.
Wirkungen der Cynara
scolymnus-Extrakte auf die Regeneration der
Rattenleber.
Maros T et al.
Arzneim-Forsch/(Drug Res) 18: 184, 1966.
No abstract.
Dicaffeoylquinic and
dicaffeoyltartaric acids are selective inhibitors
of human immunodeficiency virus type 1
integrase.
McDougall B, King PJ, Wu BW, Hostomsky Z,
Reinecke MG, Robinson WE Jr:
Antimicrob Agents Chemother 42(1): 140-6,
1998.
No abstract.
Inhibitory effect of chlorogenic acid
on methylazoxymethanolacetate-induced
carcinogenesis in large intestine and liver of
hamsters.
Mori H, Tanaka T, Shima H, Kuniyasu T,
Takahashi M
Cancer Letters 30(1):49-54, 1986.
No abstract.
Regressive effects of various
chemopreventive agents on azoxymethane-induced
aberrant crypt foci in the rat colon.
Morishita Y et al
Jpn J Cancer Res 88: 815-20. 1997
No abstract.
|